FindTrial
Sign In

Role of blood cellular mechanism in severity of COVID-19

A case control study to evaluate the role of NETosis in severity of COVID-19 patients - NETSCOV TRIAL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/10/028488
Enrollment
60
Registered
2020-10-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B342- Coronavirus infection, unspecified

Interventions

None listed

Sponsors

All India Institute of Medical Sciences Patna India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: COVID positive patients

Exclusion criteria

Exclusion criteria: Known autoimmune diseases or carcinoma Pregnancy History of severe systemic illness

Design outcomes

Primary

MeasureTime frame
Relationship between markers of NETosis (Myeloperoxidase, Elastase, Citrullinated histones and severity of COVID-19 Timepoint: Change in the clinical category of patient according to the severity—

Secondary

MeasureTime frame
1. Relationship between markers of NETosis and inflammatory markers 2. Relationship between markers of NETosis and anti inflammatory markers 3. Relationship between markers of NETosis and clinical biomarkers 4. Relationship between markers of NETosis and mortalityTimepoint: Day 1 & Day of change in severity of disease—

Countries

India

Contacts

Public ContactAbhyuday Kumar

All India Institute of Medical Sciences

drabhyu@gmail.com9013512403

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026